Theme 7 - Genotypic resistance tests for the management of patients with viro-immunological discordant response to highly active antiretroviral therapy

被引:3
作者
Moroni, M [1 ]
Rusconi, S [1 ]
机构
[1] Univ Milan, Osped Luigi Sacco, Ist Malattie Infett & Trop, Milan, Italy
关键词
D O I
10.1080/03008870310009803
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
(Single) witness: Mauro Moroni Drug resistance is one of the main factors limiting the success of antiretroviral therapy. Some other factors, such as individual enzymatic pattern and immune system function, play a role in the outcome of therapy in HIV infection. Moreover, adherence to treatment could also be a pivotal factor. Thus, there is a complex network that influences patients' response and ultimately contributes to the development of drug resistance. A particular situation among HIV-infected individuals is the finding of a 'discordant' response, which means a virological failure with the maintenance of an optimal immune function. In these subjects, the mere determination of the genotypic pattern of drug resistance is not necessary. Rather, the quantification of phenotypic drug resistance together with the measurement of viral fitness and/or CD4(+) T-cell dynamics will help in defining further therapeutic strategies.
引用
收藏
页码:85 / 87
页数:3
相关论文
共 18 条
[1]   High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy [J].
Bélec, L ;
Piketty, C ;
Si-Mohamed, A ;
Goujon, C ;
Hallouin, MC ;
Cotigny, S ;
Weiss, L ;
Kazatchkine, MD .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05) :1808-1812
[2]   Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy [J].
Clough, LA ;
D'Agata, E ;
Raffanti, S ;
Haas, DW .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (01) :75-81
[3]   Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].
Deeks, SG ;
Wrin, T ;
Liegler, T ;
Hoh, R ;
Hayden, M ;
Barbour, JD ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK ;
Grant, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480
[4]   CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy [J].
Deeks, SG ;
Hoh, R ;
Grant, RM ;
Wrin, T ;
Barbour, JD ;
Narvaez, A ;
Cesar, D ;
Abe, K ;
Hanley, MB ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (03) :315-323
[5]   HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy [J].
Deeks, SG ;
Hecht, FM ;
Swanson, M ;
Elbeik, T ;
Loftus, R ;
Cohen, PT ;
Grant, RM .
AIDS, 1999, 13 (06) :F35-F43
[6]  
FAYE A, 1999, 6 C RETR OPP INF CHI
[7]  
GAMARNIK A, 2000, ANTIVIR THER S, V5, P92
[8]   Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy [J].
Grabar, S ;
Le Moing, V ;
Goujard, C ;
Leport, C ;
Kazatchkine, MD ;
Costagliola, D ;
Weiss, L .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :401-410
[9]   CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) [J].
Kaufmann, D ;
Pantaleo, G ;
Sudre, P ;
Telenti, A .
LANCET, 1998, 351 (9104) :723-724
[10]   Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study [J].
Ledergerber, B ;
Egger, M ;
Opravil, M ;
Telenti, A ;
Hirschel, B ;
Battegay, M ;
Vernazza, P ;
Sudre, P ;
Flepp, M ;
Furrer, H ;
Francioli, P ;
Weber, R .
LANCET, 1999, 353 (9156) :863-868